You just read:

XARELTO® (rivaroxaban) Associated with Significantly Reduced Time in Hospital and Decreased Costs Compared to Standard of Care in New Study of Patients with Low-Risk Pulmonary Embolism (PE)

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Jun 14, 2018, 08:30 ET